Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy

NCT06484868 is registered in ClinicalTrials.gov with Amryt Pharma as lead sponsor.

NCT NCT06484868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06484868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy
Lead sponsor
Amryt Pharma
Phase
Phase 4
Overall status
Recruiting
Start date
February 8, 2024
Completion date
February 29, 2028
Enrollment
12 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

partial lipodystrophy